Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

VS-105

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
When using vitamin D, the most important clinical problems are hypercalcemia, hyperphosphatemia, and vascular calcification. VS… Expand
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • figure 4
2017
2017
Vitamin D receptor (VDR) agonists (VDRAs) are commonly used to treat secondary hyperparathyroidism (SHPT) associated with chronic… Expand
2016
2016
Vitamin D receptor (VDR) modulators (VDRMs) are commonly used to control secondary hyperparathyroidism (SHPT) associated with… Expand
2015
2015
Vitamin D receptor (VDR) agonists (VDRAs) are commonly used to manage hyperparathyroidism secondary to chronic kidney disease… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2015
Review
2015
Endothelial dysfunction, common in chronic kidney disease (CKD), significantly increases cardiovascular disease risk in CKD… Expand
2013
2013
We have synthesized a novel vitamin D receptor agonist VS-105 ((1R,3R)-5-((E)-2-((3αS,7αS)-1-((R)-1-((S)-3-hydroxy-2,3… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
2011
2011
BACKGROUND AND PURPOSE Vitamin D receptor (VDR) modulators (VDRMs) such as calcitriol, paricalcitol and doxercalciferol are… Expand